WO2005027895A2 - Thyroid hormone analogs and methods of use in angiogenesis - Google Patents
Thyroid hormone analogs and methods of use in angiogenesis Download PDFInfo
- Publication number
- WO2005027895A2 WO2005027895A2 PCT/US2004/030583 US2004030583W WO2005027895A2 WO 2005027895 A2 WO2005027895 A2 WO 2005027895A2 US 2004030583 W US2004030583 W US 2004030583W WO 2005027895 A2 WO2005027895 A2 WO 2005027895A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thyroid hormone
- angiogenesis
- growth factor
- analog
- polymer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
Definitions
- THYROID HORMONE ANALOGS AND METHODS OF USE FEELD OF THE INVENTION This invention relates to thyroid hormone, thyroid hormone analogs and derivatives, and polymeric form's thereof. Methods of using such compounds, and pharmaceutical compositions containing same are also disclosed. The invention also relates to methods of preparing such compounds.
- Thyroid hormones, L-thyroxin (T4) and L-triiodothyronine (T3) regulate many different physiological processes in different tissues in vertebrates. Most of the actions of thyroid hormones are mediated by the thyroid hormone receptor ("TR"), which is a member of the nuclear receptor superfamily of ligand-activated transcription regulators.
- TR thyroid hormone receptor
- TR antagonists could play an important role in the future treatment of hypothyroidism. Such molecules would act rapidly by directly antagonizing the effect of thyroid hormone at the receptor level, a significant improvement for individuals with hypothyroidism who require surgery, have cardiac disease, or are at risk for life- threatening thyrotoxic storm.
- TRs thyroid hormone receptors
- T3/T4 thyroid hormone
- Intrinsic adenosine may facilitate the coronary flow response to increased myocardial oxygen demands and so modulate the coronary flow reserve (Ethier et al., Am. J. Physiol., H131 (1993) demonstrated that the addition of physiological concentrations of adenosine to human umbilical vein endothelial cell cultures stimulates proliferation, possibly via a surface receptor.
- Adenosine may be a factor for human endothelial cell growth and possibly angiogenesis.
- Angiogenesis appears to be protective for patients with obstructive blood flow such as coronary artery disease ("CAD"), but the rate at which blood vessels grow naturally is inadequate to reverse the disease.
- CAD coronary artery disease
- strategies to enhance and accelerate the body's natural angiogenesis potential should be beneficial in patients with CAD.
- methods are provided for promoting angiogenesis along or around a medical device by coating the device with a thyroid hormone, thyroid hormone analog, or polymeric form thereof according to the invention prior to inserting the device into a patient.
- the coating step can further include coating the device with one or more biologically active substance, such as, but not limited to, a growth factor, a vasodilator, an anticoagulant, or combinations thereof.
- biologically active substance such as, but not limited to, a growth factor, a vasodilator, an anticoagulant, or combinations thereof.
- Examples of medical devices that can be coated with thyroid hormone analogs or polymeric forms according to the invention include stents, catheters, cannulas or electrodes.
- the anti-angiogenesis agent is administered by a parenteral, oral, rectal, or topical mode, or combination thereof.
- the anti-angiogenesis agent can be co-administered with one or more anti-angiogenesis therapies or chemotherapeutic agents.
- Tetrac inhibits stimulation of angiogenesis by T4 and agarose-linked T4 (T4-ag).
- T4-ag agarose-linked T4
- A A 2.5-fold increase in blood vessel branch formation is seen in a representative CAM preparation exposed to 0.1 ⁇ mol/L T4 for 3 days. In 3 similar experiments, there was a 2.3-fold increase. This effect of the hormone is inhibited by tetrac (0.1 ⁇ mol/L), a T4 analogue shown previously to inhibit plasma membrane actions of T4.13 Tetrac alone does not stimulate angiogenesis (C).
- B T4-ag (0.1 ⁇ mol/L) stimulates angiogenesis 2.3-fold (2.9-fold in 3 experiments), an effect also blocked by tetrac.
- results shown in A and B are consistent with 2 roles played by MAPK in the proangiogenic action of thyroid hormone: ERK1/2 transduces the early signal of the hormone that leads to FGF2 elaboration and transduces the subsequent action of FGF2 on angiogenesis.
- C Summary of results of 3 experiments, represented by A and B, showing the effect of PD98059 on the actions of T4 and FGF2 in the CAM model.
- T4 and FGF2 activate MAPK in ECV304 endothelial cells.
- Cells were prepared in M199 medium with 0.25% hormone-depleted serum and treated with T4 (0.1 ⁇ mol/L) for 15 minutes to 6 hours.
- Cells were harvested and nuclear fractions prepared as described previously.
- Nucleoproteins, separated by gel electrophoresis, were immunoblotted with antibody to phosphorylated MAPK (pERKl and pERK2, 44 and 42 kDa, respectively), followed by a second antibody linked to a luminescence-detection system.
- a ⁇ -actin immunoblot of nuclear fractions serves as a control for gel loading in each part of this figure.
- Each immunoblot is representative of 3 experiments.
- A T4 causes increased phosphorylation and nuclear translocation of ERK1/2 in ECV304 cells. The effect is maximal in 30 minutes, although the effect remains for >6 hours.
- B ECV304 cells were treated with the ERK1/2 activation inhibitor PD 98059 (PD; 30 ⁇ mol/L) or the PKC inhibitor CGP41251 (CGP; 100 nmol/L) for 30 minutes, after which 10 "7 M T4 was added for 15 minutes to cell samples as shown.
- FIG. 19 Polymer Compositions of Thyroid Hormone Analogs - Entrapment in a Polylactic Acid Polymer.
- Polylactic acid polyester polymers (PLA) undergo hydrolysis in vivo to the lactic acid monomer and this has been exploited as a vehicle for drug delivery systems in humans. Unlike the prior two covalent methods where the thyroid hormone analog is linked by a chemical bond to the polymer, this would be a non-covalent method that would encapsulate the thyroid hormone analog into PLA polymer beads. This reaction will lead to the formation of Thyroid hormone analog containing PLA beads in water. Filter and washing will result in the formation of thyroid hormone analog containing PLA beads, which upon in vivo hydrolysis will lead to the generation of controlled levels of thyroid hormone plus lactic acid.
- “Pharmaceutically acceptable salts” refers to pharmaceutically acceptable salts of thyroid hormone analogs, polymeric forms, and derivatives, which salts are derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetra-alkyl ammonium, and the like; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like can be used as the pharmaceutically acceptable salt.
- compositions comprising the compound to be administered can be prepared in a physiologically acceptable vehicle or carrier and optional adjuvants and preservatives.
- suitable carriers include, for example, aqueous or alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media, sterile water, creams, ointments, lotions, oils, pastes and solid carriers.
- Parenteral vehicles can include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils.
- Intravenous vehicles can include various additives, preservatives, or fluid, nutrient or electrolyte replenishers (See generally, Remington 's Pharmaceutical Science, 16th Edition, Mack, Ed. (1980)).
- Additional ingredients include, but are not limited to, one or more of the following: excipients; surface active agents; dispersing agents; inert diluents; granulating and disintegrating agents; binding agents; lubricating agents; sweetening agents; flavoring agents; coloring agents; preservatives; physiologically degradable compositions such as gelatin; aqueous vehicles and solvents; oily vehicles and solvents; suspending agents; dispersing or wetting agents; emulsifying agents, demulcents; buffers; salts; thickening agents; fillers; emulsifying agents; antioxidants; antibiotics; antifungal agents; stabilizing agents; and pharmaceutically acceptable polymeric or hydrophobic materials.
- Other “additional ingredients” which may be included in the pharmaceutical compositions of the invention are known in the art and described, e.g., in Remington 's Pharmaceutical Sciences. Compositions
- angiogenic agents comprising thyroid hormones, analogs thereof, and polymer conjugations of the hormones and their analogs.
- the disclosed compositions can be used for promoting angiogenesis to treat disorders wherein angiogenesis is beneficial. Additionally, the inhibition of these thyroid hormones, analogs and polymer conjugations can be used to inliibit angiogenesis to treat disorders associated with such undesired angiogenesis.
- angiogenic agent includes any compound or substance that promotes or encourages angiogenesis, whether alone or in combination with another substance.
- compositions of the present invention include both thyroid hormone, analogs, and derivatives either alone or in covalent or non-covalent conjugation with polymers. Examples of representative analogs and derivatives are shown in Figure 20, Tables A-D. Table A shows T2, T3, T4, and bromo-derivatives. Table B shows alanyl side chain modifications. Table C shows hydroxy groups, diphenyl ester linkages, and D-configurations. Table D shows tyrosine analogs.
- anti-angiogenesis agent or anti-angiogenic agent” refer to any compound or substance that inhibits or discourages angiogenesis, whether alone or in combination with another substance. Examples include, but are not limited to, TETRAC, TRIAC, XT 199, and mAb LM609.
- thyroid hormone analogs or polymeric forms depends upon a non-genomic initiation, as tested by the susceptibility of the hormonal effect to reduction by pharmacological inhibitors of the MAPK signal transduction pathway.
- Such results indicates that another consequence of activation of MAPK by thyroid hormone is new blood vessel growth. The latter is initiated nongenomically, but of course, requires a consequent complex gene transcription program.
- the ambient concentrations of thyroid hormone are relatively stable.
- the CAM model at the time we tested it, was thyroprival and thus may be regarded as a system, which does not reproduce the intact organism.
- CAM chick chorioallantoic membrane
- the CAM assay has been used to validate angiogenic activity of a variety of growth factors and compounds believed to promote angiogenesis.
- T in physiological concentrations was shown to be pro-angiogenic in this in vitro model and on a molar basis to have the activity of FGF2.
- the presence of PTU did not reduce the effect of T 4 , indicating that de-iodination of T 4 to generate T 3 was not a prerequisite in this model.
- a summary of the pro- angiogenesis effects of various thyroid hormone analogs is listed in Tabel 1. Table 1. Pro-angiogenesis Effects of Various Thyroid Hormone Analogs in the CAM Model
- n 8 per group
- this invention provides compositions and methods for promoting angiogenesis in a subject in need thereof.
- Conditions amenable to treatment by promoting angiogenesis include, for example, occlusive peripheral vascular disease and coronary diseases, in particular, the occlusion of coronary vessels, and disorders associated with the occlusion of the peripheral vasculature and/or coronary blood vessels, erectile dysfunction, stroke, and wounds.
- compositions and methods for promoting angiogenesis and/or recruiting collateral blood vessels in a patient in need thereof include an effective amount of polymeric forms of thyroid hormone analogs and derivatives and an effective amount of an adenosine and/or nitric oxide donor.
- compositions can be in the form of a sterile, injectable, pharmaceutical formulation that includes an angiogenically effective amount of thyroid hormone-like substance and adenosine derivatives in a physiologically and pharmaceutically acceptable carrier, optionally with one or more excipients.
- Myocardial Infarction A major reason for heart failure following acute myocardial infarction is an inadequate response of new blood vessel formation, i.e., angiogenesis.
- Thyroid hormone and its analogs are beneficial in heart failure and stimulate coronary angiogenesis.
- the methods of the invention include, in part, delivering a single treatment of a thyroid hormone analog at the time of infarction either by direct injection into the myocardium, or by simulation of coronary injection by intermittent aortic ligation to produce transient isovolumic contractions to achieve angiogenesis and/or ventricular remodeling.
- the invention features methods for treating occlusive vascular disease, coronary disease, myocardial infarction, ischemia, stroke, and/or peripheral artery vascular disorders by promoting angiogenesis by administering to a subject in need thereof an amount of a polymeric form of thyroid hormone, or an analog thereof, effective for promoting angiogenesis.
- polymeric forms of thyroid hormone analogs are also provided herein and can include triiodothyronine (T3), levothyroxine (T4), (GC-1), or 3,5-diiodothyropropionic acid (DITPA) conjugated to polyvinyl alcohol, acrylic acid ethylene co-polymer, polylactic acid, or agarose.
- the methods also involve the co-administration of an effective amount of thyroid hormone-like substance and an effective amount of an adenosine and/or NO donor in low, daily dosages for a week or more.
- One or both components can be delivered locally via catheter.
- Thyroid hormone analogs, and derivatives in vivo can be delivered to capillary beds surrounding ischemic tissue by incorporation of the compounds in an appropriately sized liposome or microparticle.
- Thyroid hormone analogs, polymeric forms and derivatives can be targeted to ischemic tissue by covalent linkage with a suitable antibody.
- the method may be used as a treatment to restore cardiac function after a myocardial infarction.
- the method may also be used to improve blood flow in patients with coronary artery disease suffering from myocardial ischemia or inadequate blood flow to areas other than the heart including, for example, occlusive peripheral vascular disease (also known as peripheral arterial occlusive disease), or erectile dysfunction.
- Wound angiogenesis is an important part of the proliferative phase of healing. Healing of any skin wound other than the most superficial cannot occur without angiogenesis. Not only does any damaged vasculature need to be repaired, but the increased local cell activity necessary for healing requires an increased supply of nutrients from the bloodstream. Moreover, the endothelial cells which form the lining of the blood vessels are important in themselves as organizers and regulators of healing.
- angiogenesis provides a new microcirculation to support the healing wound.
- the new blood vessels become clinically visible within the wound space by four days after injury.
- Vascular endothelial cells, fibroblasts, and smooth muscle cells all proliferate in coordination to support wound granulation.
- re-epithelialization occurs to reestablish the epithelial cover.
- Epithelial cells from the wound margin or from deep hair follicles migrate across the wound and establish themselves over the granulation tissue and provisional matrix. Growth factors such as keratinocyte growth factor (KGF) mediate this process.
- KGF keratinocyte growth factor
- Topical adminstration can be in the form of attachment to a band-aid.
- nano-polymers and nano-particles can be used as a marix for local delivery of thyrid hormone and its analogs. This will aid in time controlled delivery into the cellular and tissue target.
- another embodiment of the invention features methods for treating wounds by promoting angiogenesis by administering to a subject in need thereof an amount of a polymeric form of thyroid hormone, or an analog thereof, effective for promoting angiogenesis.
- a polymeric form of thyroid hormone or an analog thereof
- the invention also provides, in another part, compositions and methods for inhibiting angiogenesis in a subject in need thereof.
- Conditions amenable to treatment by inhibiting angiogenesis include, for example, primary or metastatic tumors and diabetic retinopathy.
- the compositions can include an effective amount of TETRAC, TRIAC or mAb LM609.
- the compositions can be in the form of a sterile, injectable, pharmaceutical formulation that includes an anti-angiogenically effective amount of an anti-angiogenic substance in a physiologically and pharmaceutically acceptable carrier, optionally with one or more excipients.
- the invention provides methods for treating a condition amenable to treatment by inhibiting angiogenesis by administering to a subject in need thereof an amount of an anti-angiogenesis agent effective for inhibiting angiogenesis.
- an anti-angiogenesis agent effective for inhibiting angiogenesis.
- the anti-angiogenesis agents used for inhibiting angiogenesis are also provided by the invention and include, but are not limited to, tetraiodothyroacetic acid (TETRAC), triiodothyroacetic acid (TRIAC), monoclonal antibody LM609, or combinations thereof.
- TTRAC tetraiodothyroacetic acid
- TRIAC triiodothyroacetic acid
- monoclonal antibody LM609 monoclonal antibody
- Such anti-angiogenesis agents can act at the cell surface to inhibit the pro-angiogenesis agents.
- Examples of the conditions amenable to treatment by inhibiting angiogenesis include, but are not limited to, primary or metastatic tumors.
- compounds which inhibit the thyroid hormone-induced angiogenic effect are used to inhibit angiogenesis. Details of such a method is illustrated in Example 12.
- Examples of the conditions amenable to treatment by inhibiting angiogenesis include, but are not limited to diabetic retinopathy, and related conditions.
- compounds which inhibit the thyroid hormone-induced angiogenic effect are used to inhibit angiogenesis. Details of such a method is illustrated in Examples 8 A and B.
- proliferative retinopathy induced by hypoxia depends upon alphaV ( ⁇ V) integrin expression (E Chavakis et al., Diabetologia 45:262-267, 2002). It is proposed herein that thyroid hormone action on a specific integrin alphaVbeta-3 ( ⁇ V ⁇ 3) is permissive in the development of diabetic retinopathy. Integrin ⁇ V ⁇ 3 is identified herein as the cell surface receptor for thyroid hormone. Thyroid hormone, its analogs, and polymer conjugations, act via this receptor to induce angiogenesis.
- Thyroid hormone analogs, polymeric forms, and derivatives can be used in a method for promoting angiogenesis in a patient in need thereof.
- the method involves the co-administration of an effective amount of thyroid hormone analogs, polymeric forms, and derivatives in low, daily dosages for a week or more.
- the method may be used as a treatment to restore cardiac function after a myocardial infarction.
- the method may also be used to improve blood flow in patients with coronary artery disease suffering from myocardial ischemia or inadequate blood flow to areas other than the heart, for example, peripheral vascular disease, for example, peripheral arterial occlusive disease, where decreased blood flow is a problem.
- the compounds can be administered via any medically acceptable means which is suitable for the compound to be administered, including oral, rectal, topical or parenteral (including subcutaneous, intramuscular and intravenous) administration.
- adenosine has a very short half-life. For this reason, it is preferably administered intravenously.
- adenosine A.sub.2 agonists have been developed which have much longer half-lives, and which can be administered through other means.
- Thyroid hormone analogs, polymeric forms, and derivatives can be administered, for example, intravenously, oral, topical, intranasal administration. In some embodiments, the thyroid hormone analogs, polymeric forms, and derivatives are administered via different means.
- the amounts of the thyroid hormone, its analogs, polymeric forms, and derivatives required to be effective in stimulating angiogenesis will, of course, vary with the individual being treated and is ultimately at the discretion of the physician.
- the factors to be considered include the condition of the patient being treated, the efficacy of the particular adenosine A.sub.2 receptor agonist being used, the nature of the formulation, and the patient's body weight.
- Occlusion-treating dosages of thyroid hormone analogs or its polymeric forms, and derivatives are any dosages that provide the desired effect.
- the compounds described above are preferably administered in a formulation including thyroid hormone analogs or its polymeric forms, and derivatives together with an acceptable carrier for the mode of administration.
- an acceptable carrier for the mode of administration.
- Suitable pharmaceutically acceptable carriers for oral, rectal, topical or parenteral (including subcutaneous, intraperitoneal, intramuscular and intravenous) administration are known to those of skill in the art.
- the carrier must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- Formulations suitable for parenteral administration conveniently include sterileaqueous preparation of the active compound, which is preferably isotonic with the blood of the recipient.
- sterileaqueous preparation of the active compound which is preferably isotonic with the blood of the recipient.
- Such formulations may conveniently contain distilled water, 5% dextrose in distilled water or saline.
- Useful formulations also include concentrated solutions or solids containing the compound of formula (I), which upon dilution with an appropriate solvent give a solution suitable for parental administration above.
- a compound can be incorporated into an inert carrier in discrete units such as capsules, cachets, tablets or lozenges, each containing a predetermined amount of the active compound; as a powder or granules; or a suspension or solution in an aqueous liquid or non-aqueous liquid, e.g., a syrup, an elixir, an emulsion or a draught.
- Suitable carriers may be starches or sugars and include lubricants, flavorings, binders, and other materials of the same nature.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine the active compound in a free-flowing form, e.g., a powder or granules, optionally mixed with accessory ingredients, e.g., binders, lubricants, inert diluents, surface active or dispersing agents.
- Molded tablets may be made by molding in a suitable machine, a mixture of the powdered active compound with any suitable carrier.
- a syrup or suspension may be made by adding the active compound to a concentrated, aqueous solution of a sugar, e.g., sucrose, to which may also be added any accessory ingredients.
- a sugar e.g., sucrose
- accessory ingredients may include flavoring, an agent to retard crystallization of the sugar or an agent to increase the solubility of any other ingredient, e.g., as a polyhydric alcohol, for example, glycerol or sorbitol.
- Formulations for rectal administration may be presented as a suppository with a conventional carrier, e.g., cocoa butter or Witepsol S55 (trademark of Dynamite Nobel Chemical, Germany), for a suppository base.
- a conventional carrier e.g., cocoa butter or Witepsol S55 (trademark of Dynamite Nobel Chemical, Germany)
- the compound may be administered in liposomes or microspheres (or microparticles).
- Methods for preparing liposomes and microspheres for administration to a patient are well known to those of skill in the art.
- U.S. Pat. No. 4,789,734 the contents of which are hereby incorporated by reference, describes methods for encapsulating biological materials in liposomes. Essentially, the material is dissolved in an aqueous solution, the appropriate phospholipids and lipids added, along with surfactants if required, and the material dialyzed or sonicated, as necessary.
- a review of known methods is provided by G. Gregoriadis, Chapter 14, "Liposomes,” Drag Caniers in Biology and Medicine, pp.
- Microspheres formed of polymers or proteins are well known to those skilled in the art, and can be tailored for passage through the gastrointestinal tract directly into the blood stream. Alternatively, the compound can be incorporated and the microspheres, or composite of microspheres, implanted for slow release over a period of time ranging from days to months. See, for example, U.S. Pat. Nos. 4,906,474, 4,925,673 and 3,625,214, and Jein, TIPS 19:155- 157 (1998), the contents of which are hereby incorporated by reference.
- the thyroid hormone analogs or its polymeric forms, and adenosine derivatives can be formulated into a liposome or microparticle, which is suitably sized to lodge in capillary beds following intravenous administration.
- the agents can be administered locally to the site at which they can be most effective.
- Suitable liposomes for targeting ischemic tissue are generally less than about 200 nanometers and are also typically unilamellar vesicles, as disclosed, for example, in U.S. Pat. No. 5,593,688 to Baldeschweiler, entitled "Liposomal targeting of ischemic tissue," the contents of which are hereby incorporated by reference.
- Prefened microparticles are those prepared from biodegradable polymers, such as polyglycohde, polylactide and copolymers thereof. Those of skill in the art can readily determine an appropriate carrier system depending on various factors, including the desired rate of drag release and the desired dosage.
- the formulations are administered via catheter directly to the inside of blood vessels.
- the administration can occur, for example, through holes in the catheter.
- the formulations can be included in biodegradable polymeric hydrogels, such as those disclosed in U.S. Pat. No. 5,410,016 to Hubbell et al. These polymeric hydro gels can be delivered to the inside of a tissue lumen and the active compounds released over time as the polymer degrades. If desirable, the polymeric hydrogels can have microparticles or liposomes which include the active compound dispersed therein, providing another mechanism for the controlled release of the active compounds.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active compound into association with a carrier, which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier or a finely divided solid carrier and then, if necessary, shaping the product into desired unit dosage form.
- the formulations can optionally include additional components, such as various biologically active substances such as growth factors (including TGF-.beta., basic fibroblast growth factor (FGF2), epithelial growth factor (EGF), transforming growth factors .alpha, and .beta. (TGF alpha, and beta.), nerve growth factor (NGF), platelet-derived growth factor (PDGF), and vascular endothelial growth factor/vascular permeability factor (VEGF/VPF)), antiviral, antibacterial, anti-inflammatory, immuno-suppressant, analgesic, vascularizing agent, and cell adhesion molecule.
- growth factors including TGF-.beta., basic fibroblast growth factor (FGF2), epithelial growth factor (EGF), transforming growth factors .alpha, and .beta. (TGF alpha, and beta.
- nerve growth factor NGF
- PDGF platelet-derived growth factor
- VEGF/VPF vascular endothelial growth factor/vascular
- the formulations may further include one or more optional accessory ingredient(s) utilized in the art of pharmaceutical formulations, e.g., diluents, buffers, flavoring agents, binders, surface active agents, thickeners, lubricants, suspending agents, preservatives (including antioxidants) and the like.
- optional accessory ingredient(s) utilized in the art of pharmaceutical formulations, e.g., diluents, buffers, flavoring agents, binders, surface active agents, thickeners, lubricants, suspending agents, preservatives (including antioxidants) and the like.
- T4 3,5,3 '-triiodo-L-thyronine (T3 ), tetraiodothyroacetic acid (tetrac), T4 -agarose, and 6-N-propyl-2-thiouracil (PTU) were obtained from Sigma; PD 98059 from Calbiochem; and CGP41251 was a gift from Novartis Pharma (Basel, Switzerland).
- Polyclonal anti-FGF2 and monoclonal anti- ⁇ -actin were obtained from Santa Cruz Biotechnology and human recombinant FGF2 from Invitrogen.
- Polyclonal antibody to phosphorylated ERK1/2 was from New England Biolabs and goat anti-rabbit IgG
- CAM Chorioallantoic membrane
- a window approximately 1.0 cm 2 was cut in the shell over the dropped CAM with a small-crafts grinding wheel (Dremel, division of Emerson Electric Co.), allowing direct access to the underlying CAM.
- FGF2 (1 ⁇ g/mL) was used as a standard proangiogenic agent to induce new blood vessel branches on the CAM of 10-day-old embryos.
- Sterile disks of No. 1 filter paper (Whatman International) were pretreated with 3 mg/niL cortisone acetate and 1 mmol/L PTU and air dried under sterile conditions. Thyroid hormone, hormone analogues, FGF2 or control solvents, and inhibitors were then applied to the disks and the disks allowed to dry.
- the disks were then suspended in PBS and placed on growing CAMs. Filters treated with T4 or FGF2 were placed on the first day of the 3 -day incubation, with antibody to FGF2 added 30 minutes later to selected samples as indicated. At 24 hours, the MAPK cascade inhibitor PD 98059 was also added to CAMs topically by means of the filter disks.
- ECV304 endothelial cells were cultured in M199 medium supple mented with 10% fetal bovine serum. ECV304 cells (10 6 cells) were plated on 0.2% gel-coated 24-well plates in complete medium overnight, and the cells were then washed with serum-free medium and treated with T4 or T3 as indicated. After 72 hours, the supernatants were harvested and assays for FGF performed without dilution using a commercial ELISA system (R&D Systems).
- ECV304 endothelial cells were cultured in M199 medium with 0.25% hormone-depleted serum 13 for 2 days. Cells were then treated with T4 (10 "7 mol/L) for 15 minutes to 6 hours. In additional experiments, cells were treated with T4 or FGF2 or with T4 in the presence of PD 98059 or CGP41251. Nuclear fractions were pre-pared from all samples by our method reported previously, the proteins separated by polyacrylamide gel electrophoresis, and transfened to membranes for immunoblotting with antibody to phosphorylated ERK 1/2. The appearance of nuclear phosphorylated ERK1/2 signifies activation of these MAPK isoforms by T4 .
- RNA was subjected to reverse transcription-polymerase chain reaction (RT-PCR) using the Access RT-PCR system (Promega). Total RNA was reverse transcribed into cDNA at 48°C for 45 minutes, then denatured at 94°C for 2 minutes.
- RT-PCR reverse transcription-polymerase chain reaction
- Second-strand synthesis and PCR amplification were performed for 40 cycles with denaturation at 94°C for 30 s, annealing at 60°C for 60 s, and extension at 68°C for 120 s, with final ex-tension for 7 minutes at 68°C after completion of all cycles.
- PCR primers for FGF2 were as follows: FGF2 sense strand 5'- TGGTATGTGGCACTGAAACG-3' (SEQ ID NO:l), antisense strand 5' CTCAATGACCTGGCGAAGAC-3' (SEQ ID NO:2); the length of the PCR product was 734 bp.
- Primers for GAPDH included the sense strand 5'-AAGGTCATCCCTGAGCTGAACG-3' (SEQ ID NO:3), and antisense strand 5'-GGGTGTCGCTGTTGAAGTCAGA-3' (SEQ ID NO:4); the length of the PCR product was 218 bp.
- the products of RT-PCR were separated by electrophoresis on 1.5% agarose gels and visualized with ethidium bromide. The target bands of the gel were quantified using Lablmage software (Kapelan), and the value for [FGF2/GAPDH]X10 calculated for each time point.
- Murine Angiogenesis Model The murine matrigel model will be conducted according to previously described methods (Grant et al., 1991; Okada et al., 1995) and as implemented in our laboratory (Powel et al., 2000). Briefly, growth factor free matrigel (Becton Dickinson, Bedford MA) will be thawed overnight at 4°C and placed on ice. Aliquots of matrigel will be placed into cold polypropylene tubes and FGF2, thyroid hormone analogs or cancer cells (1 x 10 6 cells) will be added to the matrigel. Matrigel with Saline, FGF2, thyroid hormone analogs or cancer cells will be subcutaneously injected into the ventral midline of the mice.
- growth factor free matrigel Becton Dickinson, Bedford MA
- FGF2 thyroid hormone analogs or cancer cells
- mice will be sacrificed and the solidified gels will be resected and analyzed for presence of new vessels.
- Compounds A-D will be injected subcutaneously at different doses.
- Control and experimental gel implants will be placed in a micro centrifuge tube containing 0.5 ml of cell lysis solution (Sigma, St. Louis, MO) and crushed with a pestle. Subsequently, the tubes will be allowed to incubate overnight at 4°C and centrifuged at 1,500 x g for 15 minutes on the following day.
- a 200 ⁇ l aliquot of cell lysate will be added to 1.3 ml of Drabkin's reagent solution (Sigma, St. Louis, MO) for each sample.
- the solution will be analyzed on a spectrophotometer at a 540 nm. The absorption of light is proportional to the amount of hemoglobin contained in the sample.
- Tumor growth and metastasis - Chick Chorioallantoic Membrane (CAM) model of tumor implant The protocol is as previously described (Kim et al., 2001). Briefly, 1 x 10 7 tumor cells will be placed on the surface of each CAM (7 day old embryo) and incubated for one week. The resulting tumors will be excised and cut into 50 mg fragments. These fragments will be placed on additional 10 CAMs per group and treated topically the following day with 25 ⁇ l of compounds (A-D) dissolved in PBS. Seven days later, tumors will then be excised from the egg and tumor weights will be determined for each CAM.
- Figure 8 is a diagrammatic sketch showing the steps involved in the in vivo tumor growth model in the CAM.
- TETRAC tumor growth rate
- TRIAC tumor angiogenesis
- tumor metastasis of cancer cell lines Tumor growth and metastasis -Tumor Xenograft model in mice'. The model is as described in our publications by Ken et al., 2000; Van Waes et al, 2000; Ali et al., 2001; and Ali et al., 2001, each of which is incorporated herein by reference in its entirety).
- the anti- cancer efficacy for TETRAC, TRIAC, and other thyroid hormone antagonists at different doses and against different tumor types can be determined and compared.
- Example 3 Enhancement of Proangiogenic Activity of FGF2 by a Submaximal Concentration of T4: Angiogenesis is a complex process that usually requires the participation of polypeptide growth factors. The CAM assay requires at least 48 hours for vessel growth to be manifest; thus, the apparent plasma membrane effects of thyroid hormone in this model are likely to result in a complex transcriptional response to the hormone. Therefore, we determined whether FGF2 was involved in the hormone response and whether the hormone might potentiate the effect of subphysiologic levels of this growth factor. T4 (0.05 ⁇ mol/L) and FGF2 (0.5 ⁇ g/mL) individually stimulated angiogenesis to a modest degree ( Figure 3).
- Thyroid hormone enhances the action of several cytokines and growth factors, such as interferon- ⁇ l3 and epidermal growth factor.
- T4 enhanced the MAPK activation caused by FGF2 in a 15-minute co incubation ( Figure 6C).
- Example 12 Inhibition of Cancer-Related New Blood Vessel Growth.
- Tetrac tetraiodothyroacetic
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004273986A AU2004273986B2 (en) | 2003-09-15 | 2004-09-15 | Thyroid hormone analogs and methods of use in angiogenesis |
JP2006526439A JP2007505837A (en) | 2003-09-15 | 2004-09-15 | Thyroid hormone analogs and methods of use in angiogenesis |
EP04784443A EP1670449B1 (en) | 2003-09-15 | 2004-09-15 | Thyroid hormone analogs and methods of use in angiogenesis |
CA2539288A CA2539288C (en) | 2003-09-15 | 2004-09-15 | Thyroid hormone analogs and methods of use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50272103P | 2003-09-15 | 2003-09-15 | |
US60/502,721 | 2003-09-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005027895A2 true WO2005027895A2 (en) | 2005-03-31 |
WO2005027895A3 WO2005027895A3 (en) | 2005-05-06 |
Family
ID=34375273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/030583 WO2005027895A2 (en) | 2003-09-15 | 2004-09-15 | Thyroid hormone analogs and methods of use in angiogenesis |
Country Status (7)
Country | Link |
---|---|
US (3) | US7785632B2 (en) |
EP (2) | EP1670449B1 (en) |
JP (2) | JP2007505837A (en) |
CN (1) | CN1878545A (en) |
AU (1) | AU2004273986B2 (en) |
CA (1) | CA2539288C (en) |
WO (1) | WO2005027895A2 (en) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006031922A2 (en) | 2004-09-15 | 2006-03-23 | Ordway Research Institute | Thyroid hormone analogs for promoting angiogenesis |
WO2007035612A2 (en) * | 2005-09-16 | 2007-03-29 | Ordway Research Institute, Inc. | Polyphenol conjugates as rgd-binding compounds and methods of use |
WO2008051291A2 (en) * | 2006-04-11 | 2008-05-02 | Ordway Research Institute | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
WO2008140507A3 (en) * | 2006-12-22 | 2008-12-31 | Clf Medical Technology Acceleration Program Inc | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
JP2009533453A (en) * | 2006-04-11 | 2009-09-17 | オードウェイ リサーチ インスティテュート | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and their formulations |
US7785632B2 (en) | 2003-09-15 | 2010-08-31 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use |
US7829552B2 (en) | 2003-11-19 | 2010-11-09 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyromimetics |
US8071134B2 (en) | 2003-09-15 | 2011-12-06 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use |
US8668926B1 (en) | 2003-09-15 | 2014-03-11 | Shaker A. Mousa | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
US8802240B2 (en) | 2011-01-06 | 2014-08-12 | Nanopharmaceuticals Llc | Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells |
US9180107B2 (en) | 2009-03-31 | 2015-11-10 | Nanopharmaceuticals Llc | Combination treatment of cancer with cetuximab and tetrac |
US9198887B2 (en) | 2003-09-15 | 2015-12-01 | Nanopharmaceuticals Llc | Thyroid hormone analogs and methods of use |
US9220788B2 (en) | 2009-06-17 | 2015-12-29 | Nanopharmaceuticals Llc | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
US9498536B2 (en) | 2005-09-15 | 2016-11-22 | Nanopharmaceuticals Llc | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders |
EP3259012A4 (en) * | 2015-02-16 | 2018-09-19 | CardioVascular BioTherapeutics, Inc. | Therapeutic angiogenesis for treating erectile conditions |
US10130643B2 (en) | 2005-05-26 | 2018-11-20 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
US10130686B2 (en) | 2005-09-15 | 2018-11-20 | Nanopharmaceuticals Llc | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders |
US10201616B2 (en) | 2016-06-07 | 2019-02-12 | Nanopharmaceuticals, Llc | Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonists |
US10328043B1 (en) | 2018-04-11 | 2019-06-25 | Nanopharmaceuticals, Llc. | Composition and method for dual targeting in treatment of neuroendocrine tumors |
US10946001B2 (en) | 2016-03-10 | 2021-03-16 | Io Therapeutics, Inc. | Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones |
US10961204B1 (en) | 2020-04-29 | 2021-03-30 | Nanopharmaceuticals Llc | Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors |
US11166927B2 (en) | 2011-12-13 | 2021-11-09 | Io Therapeutics, Inc. | Autoimmune disorder treatment using RXR agonists |
US11351137B2 (en) | 2018-04-11 | 2022-06-07 | Nanopharmaceuticals Llc | Composition and method for dual targeting in treatment of neuroendocrine tumors |
US11517549B2 (en) | 2017-09-20 | 2022-12-06 | Io Therapeutics, Inc. | Treatment of disease with esters of selective RXR agonists |
WO2023025388A1 (en) * | 2021-08-26 | 2023-03-02 | Technische Universität Graz | System and method for measuring and device for determining a required drug dosage |
US11723888B2 (en) | 2021-12-09 | 2023-08-15 | Nanopharmaceuticals Llc | Polymer conjugated thyrointegrin antagonists |
US11896558B2 (en) | 2021-12-07 | 2024-02-13 | Io Therapeutics, Inc. | Use of an RXR agonist and taxanes in treating Her2+ cancers |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100159021A1 (en) * | 2008-12-23 | 2010-06-24 | Paul Davis | Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use |
US8404281B2 (en) * | 2009-06-08 | 2013-03-26 | Avant Garde Therapeutics & Technologies Llc | Formulations |
WO2014178892A1 (en) * | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
US10060934B2 (en) | 2013-11-18 | 2018-08-28 | Nanopharmaceuticals Llc | Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof |
DK3426303T3 (en) * | 2016-03-10 | 2022-09-19 | Io Therapeutics Inc | TREATMENT OF MUSCLE DISORDERS WITH COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES |
CN111419834A (en) * | 2020-04-17 | 2020-07-17 | 上海交通大学医学院附属瑞金医院 | Application of thyroid hormone and thyroid hormone analogue in preparation of drugs for treating sickle cell disease |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3625214A (en) | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
IL51354A (en) * | 1977-01-28 | 1979-07-25 | Ames Yissum Ltd | Assay method for the quantitative determination of a hapten in aqueous solution |
US4906474A (en) | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
US4650751A (en) * | 1983-04-29 | 1987-03-17 | Technicon Instruments Corporation | Protected binding assay avoiding non-specific protein interference |
US4719182A (en) * | 1985-03-18 | 1988-01-12 | Eastman Kodak Company | Fluorescent labels and labeled species and their use in analytical elements and determinations |
US4789734A (en) | 1985-08-06 | 1988-12-06 | La Jolla Cancer Research Foundation | Vitronectin specific cell receptor derived from mammalian mesenchymal tissue |
US5449665A (en) * | 1985-09-24 | 1995-09-12 | Item Development Aktiebolag | Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty |
US4801575A (en) | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
EP0318512B1 (en) | 1986-08-18 | 1998-06-17 | Emisphere Technologies, Inc. | Delivery systems for pharmacological agents |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5231000A (en) | 1987-10-08 | 1993-07-27 | The Mclean Hospital | Antibodies to A4 amyloid peptide |
IT1216687B (en) * | 1988-04-01 | 1990-03-08 | Boehringer Biochemia Srl | PLATINUM (II) COMPLEXES, THEIR PREPARATION AND USE AS ANTI-CANCER PRODUCTS. |
US4968590A (en) | 1988-04-08 | 1990-11-06 | Stryker Corporation | Osteogenic proteins and polypeptides |
US5011486A (en) | 1988-11-18 | 1991-04-30 | Brown University Research Foundation | Composite nerve guidance channels |
US5635482A (en) * | 1989-08-14 | 1997-06-03 | The Regents Of The University Of California | Synthetic compounds and compositions with enhanced cell binding |
US5438126A (en) * | 1989-09-11 | 1995-08-01 | Arch Development Corporation | Human thyroid hormone receptor DNA |
US5304121A (en) * | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5158978A (en) * | 1990-02-05 | 1992-10-27 | British Technology Group (U.S.A.) | Thyroid hormone treatment of acute cardiovascular compromise |
US5410016A (en) | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US5773574A (en) * | 1990-12-03 | 1998-06-30 | The Scripps Research Institute | Polypeptides for promoting cell attachment |
US5766635A (en) * | 1991-06-28 | 1998-06-16 | Rhone-Poulenc Rorer S.A. | Process for preparing nanoparticles |
US5591709A (en) * | 1991-08-30 | 1997-01-07 | Life Medical Sciences, Inc. | Compositions and methods for treating wounds |
US5225204A (en) * | 1991-11-05 | 1993-07-06 | Chen Jivn Ren | Stable dosage of levothyroxine sodium and process of production |
AU3129793A (en) * | 1991-11-08 | 1993-06-07 | General Hospital Corporation, The | Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration |
WO1993024476A1 (en) * | 1992-06-04 | 1993-12-09 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
US5482719A (en) * | 1992-10-30 | 1996-01-09 | Guillet; James E. | Drug delivery systems |
US5571840A (en) * | 1993-06-22 | 1996-11-05 | The Regents Of The University Of Michigan | Method for treating central nervous system ischemia |
US5593688A (en) | 1993-06-25 | 1997-01-14 | Nexstar Pharmaceuticals, Inc. | Liposomal targeting of ischemic tissue |
US5773252A (en) * | 1995-06-05 | 1998-06-30 | Human Genome Sciences, Inc. | Fibroblast growth factor 15 |
PT831769E (en) * | 1995-06-07 | 2004-02-27 | Karobio Ab | NEW USES FOR TIROIDE HORMONES OR TIROIDE HORMONES SIMILAR |
CN1126589A (en) | 1995-06-09 | 1996-07-17 | 中国科学院成都有机化学研究所 | Injecta of delayed hormone microcapsule and its prepn |
AU719365B2 (en) | 1995-09-28 | 2000-05-04 | Sangstat Medical Corporation | Use of hyaluronic acid as an immunosuppressant |
FR2742357B1 (en) * | 1995-12-19 | 1998-01-09 | Rhone Poulenc Rorer Sa | STABILIZED AND FILTRABLE NANOPARTICLES UNDER STERILE CONDITIONS |
US6596712B2 (en) * | 1996-04-26 | 2003-07-22 | Genaera Corporation | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
DE69837968D1 (en) | 1997-01-30 | 2007-08-02 | Univ Technology Corp | DIAGNOSIS AND TREATMENT OF MYOCARDIAL ERRORS |
US6207665B1 (en) | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
US5994309A (en) * | 1997-07-25 | 1999-11-30 | Angstrom Pharmaceuticals, Inc. | Anti-invasive and anti-angiogenic compositions and methods |
US6414037B1 (en) | 1998-01-09 | 2002-07-02 | Pharmascience | Pharmaceutical formulations of resveratrol and methods of use thereof |
US6482406B1 (en) * | 1999-03-26 | 2002-11-19 | Duncan J. Stewart | Cell-based gene therapy for the pulmonary system |
US6022901A (en) | 1998-05-13 | 2000-02-08 | Pharmascience Inc. | Administration of resveratrol to prevent or treat restenosis following coronary intervention |
KR19990085365A (en) * | 1998-05-16 | 1999-12-06 | 허영섭 | Biodegradable polymer microspheres capable of continuously controlled controlled release and preparation method thereof |
EP1083928A4 (en) | 1998-06-04 | 2002-05-22 | Sinai School Medicine | Method of inhibiting angiogenesis and tumor growth and preventing tumor growth and metastases |
CA2246791A1 (en) * | 1998-09-01 | 2000-03-01 | Alison Buchan | Treatment of endothelium with somatostatin analogues |
US6521593B1 (en) * | 1999-02-01 | 2003-02-18 | Childrens Hospital Los Angeles | Methods for inhibiting brain tumor growth |
US6740680B1 (en) | 1999-04-26 | 2004-05-25 | Becton Pharma, Inc. | Pharmaceutical compositions to tetrac and methods of use thereof |
WO2000064431A1 (en) * | 1999-04-26 | 2000-11-02 | Danforth Elliot Jr | Pharmaceutical compositions of tetrac and methods of use thereof |
US6776984B1 (en) | 1999-08-20 | 2004-08-17 | George R. Schwartz | Induced regeneration and repair of damaged neurons and nerve axon myelin |
US6531580B1 (en) | 1999-06-24 | 2003-03-11 | Ixsys, Inc. | Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same |
WO2001013031A2 (en) | 1999-08-13 | 2001-02-22 | Chiron Corporation | Dose of an angiogenic factor and method of administering to improve myocardial blood flow |
AU1624801A (en) * | 1999-11-19 | 2001-05-30 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists related applications |
US20020049247A1 (en) * | 2000-01-12 | 2002-04-25 | Chen James C. | Novel treatment for eye disease |
FI107018B (en) | 2000-04-06 | 2001-05-31 | Ipsat Therapies Oy | Dermatological use and dermatological preparation |
CN100548375C (en) * | 2000-06-23 | 2009-10-14 | 田边三菱制药株式会社 | Antitumor effect potentiators |
US20020077364A1 (en) * | 2000-07-06 | 2002-06-20 | Ramaswamy Murari | Thyroid hormone formulations |
JP2004528278A (en) | 2000-12-18 | 2004-09-16 | ボード オブ レジェンツ,ザ ユニバーシティー オブ テキサス システム | Localized area chemotherapy and radiation treatment using in situ hydrogel |
US6534676B2 (en) | 2001-01-31 | 2003-03-18 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same |
DE02717541T1 (en) | 2001-05-07 | 2004-08-26 | Cornell Research Foundation, Inc. | BIODEGRADABLE COPOLYMERS TIED TO A SEGMENT WITH SEVERAL FUNCTIONAL GROUPS |
US6645526B2 (en) * | 2001-11-13 | 2003-11-11 | Mylan Pharmaceuticals, Inc. | Storage stable thyroxine active drug formulations and methods for their production |
US6821947B2 (en) | 2001-12-04 | 2004-11-23 | Thomas Jefferson University | Endorepellin: methods and compositions for inhibiting angiogenesis |
CA2468989A1 (en) * | 2001-12-07 | 2003-06-19 | Daniel M. Schwartz | Treatment for age-related macular degeneration |
US6720008B2 (en) * | 2002-01-22 | 2004-04-13 | Pr Pharmaceuticals, Inc. | Composition and method for the encapsulation of water-soluble molecules into nanoparticles |
WO2003075741A2 (en) | 2002-03-04 | 2003-09-18 | Medimmune, Inc. | METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE |
WO2003084470A2 (en) * | 2002-04-02 | 2003-10-16 | Arizeke Pharmaceuticals, Inc. | Compositions and methods for targeted biological delivery of molecular carriers |
EP1354953A1 (en) | 2002-04-17 | 2003-10-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Smac-peptides as therapeutics against cancer and autoimmune diseases |
US20040024749A1 (en) | 2002-08-01 | 2004-02-05 | Omega Systems, Inc. | Automated system and method for reviewing medical and financial claim records and for identifying missing devices and/or services associated with medical and financial procedures |
EP1422311B1 (en) | 2002-11-19 | 2007-02-28 | Hitachi Tool Engineering Ltd. | Hard film and hard film coated tool |
WO2004069201A2 (en) | 2003-02-03 | 2004-08-19 | Medlogics Device Corporation | Compounds useful in coating stents to prevent and treat stenosis and restenosis |
EP1592709A2 (en) | 2003-02-10 | 2005-11-09 | TO-BBB Holding B.V. | Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions |
US9149440B2 (en) | 2003-09-02 | 2015-10-06 | University Of South Florida | Nanoparticles for drug-delivery |
US8668926B1 (en) | 2003-09-15 | 2014-03-11 | Shaker A. Mousa | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
WO2006031922A2 (en) | 2004-09-15 | 2006-03-23 | Ordway Research Institute | Thyroid hormone analogs for promoting angiogenesis |
US8071134B2 (en) | 2003-09-15 | 2011-12-06 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use |
US9198887B2 (en) | 2003-09-15 | 2015-12-01 | Nanopharmaceuticals Llc | Thyroid hormone analogs and methods of use |
EP1670449B1 (en) | 2003-09-15 | 2012-06-27 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use in angiogenesis |
US20050158376A1 (en) | 2003-10-23 | 2005-07-21 | Sardi William F. | Dietary supplement and method of processing same |
US7407973B2 (en) | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
JP2007527418A (en) | 2003-12-29 | 2007-09-27 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Composition for treating or preventing obesity and insulin resistance disorders |
US20080193377A1 (en) * | 2004-06-28 | 2008-08-14 | University Of Maryland, Baltimore | Radiolabeled Nanohybrids Targeting Solid Tumor Neovasculature and Method of Using Same |
US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
US20060166303A1 (en) | 2005-01-24 | 2006-07-27 | Eberhard Spanuth | Use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs |
EP2314614B1 (en) * | 2005-02-28 | 2015-11-25 | Sangamo BioSciences, Inc. | Anti-angiogenic methods and compositions |
WO2006107903A2 (en) | 2005-04-01 | 2006-10-12 | Intezyne Technologies, Incorporated | Polymeric micelles for drug delivery |
US9498536B2 (en) | 2005-09-15 | 2016-11-22 | Nanopharmaceuticals Llc | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders |
US10130686B2 (en) | 2005-09-15 | 2018-11-20 | Nanopharmaceuticals Llc | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders |
US20090022806A1 (en) | 2006-12-22 | 2009-01-22 | Mousa Shaker A | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof |
US20100209382A1 (en) | 2005-09-16 | 2010-08-19 | Ordway Research Institute, Inc. | Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use |
EP1934599A1 (en) | 2005-10-11 | 2008-06-25 | Merck Patent GmbH | Egfr dependent modulation of chemokine expression and influence on therapy and diagnosis of tumors and side effects thereof |
CN101366294A (en) | 2005-10-31 | 2009-02-11 | 艾利森电话股份有限公司 | Method and system for existence of mobile station in at least one special service zone of mobile telecommunication system |
EP2018186A2 (en) | 2006-04-11 | 2009-01-28 | Ordway Research Institute, Inc. | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
JP5630998B2 (en) | 2006-05-15 | 2014-11-26 | マサチューセッツ インスティテュート オブ テクノロジー | Polymers for functional particles |
WO2007146414A2 (en) | 2006-06-15 | 2007-12-21 | Biogen Idec Ma Inc. | Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents |
JP2010513526A (en) | 2006-12-22 | 2010-04-30 | シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof |
WO2009089027A1 (en) | 2008-01-09 | 2009-07-16 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Service, National Institutes Of Health | Phosphodiesterase inhibitors |
US20100159021A1 (en) | 2008-12-23 | 2010-06-24 | Paul Davis | Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use |
US9180107B2 (en) | 2009-03-31 | 2015-11-10 | Nanopharmaceuticals Llc | Combination treatment of cancer with cetuximab and tetrac |
EP2442800B1 (en) | 2009-06-17 | 2019-04-24 | NanoPharmaceuticals LLC | Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof |
EP2575816B1 (en) | 2010-05-28 | 2019-01-02 | Nexgen Dermatologics, Inc. | Combination therapy for skin disorders |
US8802240B2 (en) | 2011-01-06 | 2014-08-12 | Nanopharmaceuticals Llc | Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells |
-
2004
- 2004-09-15 EP EP04784443A patent/EP1670449B1/en not_active Not-in-force
- 2004-09-15 CA CA2539288A patent/CA2539288C/en not_active Expired - Fee Related
- 2004-09-15 EP EP10185609.4A patent/EP2335694B1/en not_active Not-in-force
- 2004-09-15 WO PCT/US2004/030583 patent/WO2005027895A2/en active Application Filing
- 2004-09-15 CN CNA2004800331846A patent/CN1878545A/en active Pending
- 2004-09-15 JP JP2006526439A patent/JP2007505837A/en active Pending
- 2004-09-15 US US10/943,072 patent/US7785632B2/en not_active Expired - Fee Related
- 2004-09-15 AU AU2004273986A patent/AU2004273986B2/en not_active Ceased
-
2009
- 2009-11-25 US US12/626,068 patent/US8518451B2/en active Active
-
2010
- 2010-11-30 JP JP2010267623A patent/JP2011042691A/en not_active Withdrawn
-
2013
- 2013-08-26 US US13/975,725 patent/US9980933B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
E CHAVAKIS ET AL., DIABETOLOGIA, vol. 45, 2002, pages 262 - 267 |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9198887B2 (en) | 2003-09-15 | 2015-12-01 | Nanopharmaceuticals Llc | Thyroid hormone analogs and methods of use |
US8071134B2 (en) | 2003-09-15 | 2011-12-06 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use |
US8518451B2 (en) | 2003-09-15 | 2013-08-27 | Albany College of Pharmacy and Health Services | Thyroid hormone analogs and methods of use |
US9750709B2 (en) | 2003-09-15 | 2017-09-05 | Nanopharmaceuticals Llc | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
US9579300B2 (en) | 2003-09-15 | 2017-02-28 | Nanopharmaceuticals Llc | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
US9980933B2 (en) | 2003-09-15 | 2018-05-29 | Nanopharmaceuticals Llc | Thyroid hormone analogs and methods of use |
US7785632B2 (en) | 2003-09-15 | 2010-08-31 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use |
US8668926B1 (en) | 2003-09-15 | 2014-03-11 | Shaker A. Mousa | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
US7829552B2 (en) | 2003-11-19 | 2010-11-09 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyromimetics |
WO2006031922A2 (en) | 2004-09-15 | 2006-03-23 | Ordway Research Institute | Thyroid hormone analogs for promoting angiogenesis |
WO2006031922A3 (en) * | 2004-09-15 | 2007-03-01 | Ordway Res Inst | Thyroid hormone analogs for promoting angiogenesis |
US10130643B2 (en) | 2005-05-26 | 2018-11-20 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
US10130686B2 (en) | 2005-09-15 | 2018-11-20 | Nanopharmaceuticals Llc | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders |
US9498536B2 (en) | 2005-09-15 | 2016-11-22 | Nanopharmaceuticals Llc | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders |
WO2007035612A2 (en) * | 2005-09-16 | 2007-03-29 | Ordway Research Institute, Inc. | Polyphenol conjugates as rgd-binding compounds and methods of use |
US9272049B2 (en) | 2005-09-16 | 2016-03-01 | Nanopharmaceuticals Llc | Methods of stimulating fat mobilization using a polymer conjugated polyphenol |
WO2007035612A3 (en) * | 2005-09-16 | 2007-09-20 | Ordway Res Inst Inc | Polyphenol conjugates as rgd-binding compounds and methods of use |
JP2009533453A (en) * | 2006-04-11 | 2009-09-17 | オードウェイ リサーチ インスティテュート | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and their formulations |
WO2008051291A3 (en) * | 2006-04-11 | 2008-12-24 | Ordway Res Inst | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
WO2008051291A2 (en) * | 2006-04-11 | 2008-05-02 | Ordway Research Institute | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
WO2008140507A3 (en) * | 2006-12-22 | 2008-12-31 | Clf Medical Technology Acceleration Program Inc | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
US9289395B2 (en) | 2006-12-22 | 2016-03-22 | Nanopharmaceuticals Llc | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
US9180107B2 (en) | 2009-03-31 | 2015-11-10 | Nanopharmaceuticals Llc | Combination treatment of cancer with cetuximab and tetrac |
US9839614B2 (en) | 2009-06-17 | 2017-12-12 | Nanopharmaceuticals, Llc | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
US9220788B2 (en) | 2009-06-17 | 2015-12-29 | Nanopharmaceuticals Llc | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
US8802240B2 (en) | 2011-01-06 | 2014-08-12 | Nanopharmaceuticals Llc | Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells |
US11547684B2 (en) | 2011-12-13 | 2023-01-10 | Io Therapeutics, Inc. | Autoimmune disorder treatment using RXR agonists |
US11793781B2 (en) | 2011-12-13 | 2023-10-24 | Io Therapeutics, Inc. | Autoimmune disorder treatment using RXR agonists |
US11166927B2 (en) | 2011-12-13 | 2021-11-09 | Io Therapeutics, Inc. | Autoimmune disorder treatment using RXR agonists |
US11576881B2 (en) | 2011-12-13 | 2023-02-14 | Io Therapeutics, Inc. | Autoimmune disorder treatment using RXR agonists |
US11246845B2 (en) | 2011-12-13 | 2022-02-15 | Io Therapeutics, Inc. | Autoimmune disorder treatment using RXR agonists |
EP3259012A4 (en) * | 2015-02-16 | 2018-09-19 | CardioVascular BioTherapeutics, Inc. | Therapeutic angiogenesis for treating erectile conditions |
AU2016220304B2 (en) * | 2015-02-16 | 2019-07-25 | Venturis Therapeutics, Inc. | Therapeutic angiogenesis for treating erectile conditions |
US10946001B2 (en) | 2016-03-10 | 2021-03-16 | Io Therapeutics, Inc. | Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones |
US11690832B2 (en) | 2016-03-10 | 2023-07-04 | Io Therapeutics | Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones |
US11690831B2 (en) | 2016-03-10 | 2023-07-04 | Io Therapeutics, Inc. | Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones |
US10695436B2 (en) | 2016-06-07 | 2020-06-30 | Nanopharmaceuticals, Llc | Non-cleavable polymer conjugated with alpha V beta 3 integrin thyroid antagonists |
US10201616B2 (en) | 2016-06-07 | 2019-02-12 | Nanopharmaceuticals, Llc | Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonists |
US11517549B2 (en) | 2017-09-20 | 2022-12-06 | Io Therapeutics, Inc. | Treatment of disease with esters of selective RXR agonists |
US11351137B2 (en) | 2018-04-11 | 2022-06-07 | Nanopharmaceuticals Llc | Composition and method for dual targeting in treatment of neuroendocrine tumors |
US11077082B2 (en) | 2018-04-11 | 2021-08-03 | Nanopharmaceuticals, Llc | Composition and method for dual targeting in treatment of neuroendocrine tumors |
US10328043B1 (en) | 2018-04-11 | 2019-06-25 | Nanopharmaceuticals, Llc. | Composition and method for dual targeting in treatment of neuroendocrine tumors |
US11186551B2 (en) | 2020-04-29 | 2021-11-30 | Nanopharmaceuticals Llc | Composition of scalable thyrointegrin antagonists with improved retention in tumors |
US10961204B1 (en) | 2020-04-29 | 2021-03-30 | Nanopharmaceuticals Llc | Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors |
WO2023025388A1 (en) * | 2021-08-26 | 2023-03-02 | Technische Universität Graz | System and method for measuring and device for determining a required drug dosage |
US11896558B2 (en) | 2021-12-07 | 2024-02-13 | Io Therapeutics, Inc. | Use of an RXR agonist and taxanes in treating Her2+ cancers |
US11723888B2 (en) | 2021-12-09 | 2023-08-15 | Nanopharmaceuticals Llc | Polymer conjugated thyrointegrin antagonists |
Also Published As
Publication number | Publication date |
---|---|
CN1878545A (en) | 2006-12-13 |
US20100112079A1 (en) | 2010-05-06 |
CA2539288C (en) | 2015-05-12 |
EP1670449B1 (en) | 2012-06-27 |
WO2005027895A3 (en) | 2005-05-06 |
US9980933B2 (en) | 2018-05-29 |
EP1670449A2 (en) | 2006-06-21 |
AU2004273986A1 (en) | 2005-03-31 |
JP2007505837A (en) | 2007-03-15 |
CA2539288A1 (en) | 2005-03-31 |
US20140072646A1 (en) | 2014-03-13 |
US8518451B2 (en) | 2013-08-27 |
EP2335694A1 (en) | 2011-06-22 |
JP2011042691A (en) | 2011-03-03 |
US20050124862A1 (en) | 2005-06-09 |
US7785632B2 (en) | 2010-08-31 |
EP2335694B1 (en) | 2018-06-13 |
AU2004273986B2 (en) | 2010-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9980933B2 (en) | Thyroid hormone analogs and methods of use | |
US9198887B2 (en) | Thyroid hormone analogs and methods of use | |
JP2007505837A5 (en) | ||
US9579300B2 (en) | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof | |
US9289395B2 (en) | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof | |
EP1793814B1 (en) | Thyroid hormone analogs for inhibiting angiogenesis | |
CA2648243C (en) | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof | |
US8071134B2 (en) | Thyroid hormone analogs and methods of use | |
US7741311B2 (en) | Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing | |
US20090022806A1 (en) | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof | |
US7736636B2 (en) | Method for treating occlusive vascular diseases & wound healing | |
US20060104944A1 (en) | Activators and inhibitors of protease activated receptor2 (PAR2) and methods of use | |
US20100080843A1 (en) | Natural and synthetic sulfur and selenium analogs and polymer conjugated forms thereof for the modulation of angiogenesis | |
JP2009533453A (en) | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and their formulations | |
CA2805552C (en) | Polymeric conjugates of anti-angiogenesis agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480033184.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006526439 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2539288 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004273986 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1907/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004784443 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004273986 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004784443 Country of ref document: EP |